Prostate cancer is a common malignant tumor in male genitourinary system, and radical prostatectomy is one of the important methods to treat prostate cancer. Indocyanine green is a non-radioactive, water-soluble compound, which can help identify anatomical structures and visualize blood vessels through near-infrared fluorescence. The role and injection techniques of Indocyanine green in radical prostatectomy in sentinel lymph node identification, pelvic lymph node dissection and neurovascular bundle preservation are reviewed, so as to provide a reference for improving the surgical effect, reducing the difficulty of surgery, and prolonging the survival period of patients, and evaluate the potential research field of this technology in the future.

Cystitis glandularis is a hyperplastic disease originated from the bladder mucosa, cystitis glandularis is a rare clinical disease, there is no standard diagnosis and treatment. The etiology and pathogenesis of cystitis glandularis are still unknown, it can be diagnosed according to clinical manifestations, laboratory and auxiliary examinations, and the diagnosis of cystitis glandularis mainly depends on pathological results. Cystitis glandularis has a cancerous tendency. The clinical treatment methods of cystitis glandularis include conservative treatment, surgical treatment and surgical combined with drug therapy, but different types of treatment methods are different, and most patients are treated by surgery combined with drug perfusion of the bladder.This article will review the research progress in diagnosis and treatment of cystitis glandularis.

Objective:To investigate the effectiveness of enhanced recovery after surgery (ERAS) concept in perioperative period of retroperitoneal laparoscopic radical nephrectomy.Methods:The clinical data of 189 patients who underwent retroperitoneal laparoscopic radical nephrectomy from October 2015 to July 2021 were retrospectively analyzed. According to different perioperative management methods, they were divided into two groups: ERAS group ( n=97) and traditional group ( n=92). Patients of ERAS group were managed by the ERAS concept during the perioperative period, patients of traditional group were managed by the traditional method during the perioperative period. First drinking time after surgery, first exhaust time, 24 h postoperative pain score, first activity time out of bed, indwelling time of urinary catheter, indwelling time of drainage tube, postoperative hospital stay, incision length and complications of pneumonia and venous thrombosis were recorded and compared between the two groups. Measurement data were expressed as mean ± standard deviation ( Mean± SD), and independent sample t-test was used for comparison between groups; count data comparison between groups was by Chi-square test or Fisher exact probability method. Results:There were no significant differences in age, gender, body mass index, tumor side, tumor diameter, maximum diameter of samples, T stage, diabetes and hypertension from between two groups ( P >0.05). In ERAS group, the time of first drinking water after surgery was (3.8±1.4) h, the time of first anal exhaust was (10.2±2.5) h, the 24 h pain score was (2.4±1.0), the time of first activity out of bed after surgery was (18.8±3.6) h, the indwelling time of urinary catheter was (19.8±3.7) h, the indwelling time of drainage tube was (3.4±0.5) d, the surgical incision length was (7.2±0.9) cm, and the postoperative hospital stay was (5.5±0.6) d. In the traditional group, the time of first drinking water after surgery was (21.2±4.2) h, the time of first anal exhaust was (20.1±4.3) h, the 24 h pain score was (5.4±1.0), the time of first activity out of bed after surgery was (32.8±7.8) h, the indwelling time of urinary catheter was (55.7±8.0) h, the indwelling time of drainage tube was (4.2±0.5) d, the surgical incision length was (13.6±1.5) cm, and the postoperative hospital stay was (7.2±1.3) d. There were statistically significant differences in these indexes between the two groups ( P<0.05). Conclusion:The clinical application of the concept of ERAS during the perioperative period can promote the rapid postoperative recovery of patients undergoing retroperitoneal laparoscopic radical nephrectomy, and can effectively reflect the minimally invase advantages of retroperitoneal laparoscopic technology.

Gleason grading system is a critical factor for assessing the risk, making treatment decision and evaluating prognosis for patients with prostate cancer. However, it has been reported that concordance rates of Gleason score between biopsy pathology and radical prostatectomy specimen were only39%-63%, whilst postsurgical upgrade and downgrade rates were 30%-55% and 7%-20% respectively. This situation brings difficulties in performing clinical practice. This literature aimed to review relevant and updated studies in literature to summarize the concordance rate and independent predictive factors of Gleason score change from following several aspects: patient clinical characteristics, biopsy-related factors, accuracy of pathologic assignment and interpretation of pathology reports. This review also investigated how the factors influenced the Gleason score change and clinical decision-making. There were many factors influencing the Gleason score change which were roughly consistent with risk factors of prostate cancer, however, some factors were controversial. In order to provide precise evaluation of risk stratification and optimal individualized treatment, it is essential to consider the risk factors which are correlated with Gleason score change.

Objective:To analyze the risk factors of stress urinary incontinence after transurethral enucleation of prostate.Methods:A retrospective analysis of the clinical data of 326 patients who underwent transurethral enucleation of prostate at the Beijing Friendship Hospital, Capital Medical University due to benign prostatic hyperplasia from March 2016 to December 2019. Patients were divided into stress urinary incontinence group ( n=78) and non-stress urinary incontinence group ( n=248) according to whether there was stress urinary incontinence one week after the catheter was removed. Age, body mass index, hypertension, diabetes, hyperlipidemia, prostate volume, the time of lower urinary tract symptoms (LUTS), total prostate specific antigen, preoperative indwelling catheter status, operation type, operation time, percentage of hemoglobin reduction and catherization time were compared between the two groups. Measurement data were expressed as mean±standard deviation ( Mean± SD), and t-test was used for comparison between groups; Chi-square test or Fisher exact probability method was used for comparison of count data between groups. Single factor and multivariate Logistic regression analysis were used to screen independent predictors. Results:Age [(73.9±7.3) years vs (69.5±7.8) years, P<0.001], body mass index [(25.6±3.0) kg/m 2vs (24.6±2.9) kg/m 2, P=0.004], the time of LUTS [(5.42±5.65) years vs (5.05±5.19) years, P=0.008], and hypertension (57.7% vs 43.6%, P=0.037), prostate volume [(77.1±33.2) mL vs (62.5±30.2) mL, P<0.001], operation time [(115.0±45.7) min vs (99.8±41.4) min, P=0.006] in stress urinary incontinence group were significantly higher than those in the non-stress urinary incontinence group, the differences were statistically significant. Age ( OR=1.05, 95% CI: 1.02-1.07, P<0.001), body mass index ( OR=1.08, 95% CI: 1.03-1.14, P=0.003), LUTS ( OR=1.21, 95% CI: 1.14-1.29, P=0.015)and prostate volume ( OR=1.11, 95% CI: 1.10-1.11, P=0.011) were independent risk factors for stress urinary incontinence after transurethral enucleation of prostate by multivariate Logistic regression analysis. Conclusion:Age≥70years, body mass index≥25 kg/m 2, LUTS during≥5 years and prostate volume≥75 mL are independent risk factors for stress urinary incontinence after transurethral enucleation of prostate.

Adrenal gland is one of the most common metastases from malignant tumors. Most adrenal metastases have not completely destroyed adrenal tissue, so most patients have no clinical symptoms. The main methods for the diagnosis of adrenal metastases are CT, magnetic resonance imaging and positron emission tomography. At present, there is still controversy about the treatment of adrenal metastasis of all kinds of adrenal metastases. Non-surgical treatment mainly includes chemical drug therapy, radiotherapy, interventional therapy and so on. With the development of cognition and technology, the mode and indication of surgical treatment have also changed. In this paper, the diagnosis and treatment of adrenal metastases in recent years are reviewed.

Adrenocortical carcinoma is a malignant endocrine tumor.There is no unified standard for diagnosis and treatment because of the low incidence.There are two peaks in the age of onset,which are 0 to 10 years and 40 to 50 years,and the incidence of children and women is higher.The percentage of 60 to 70 ACC patients show clinical symptoms due to the excess hormone,but there are still many patients with poor clinical symptoms.The common endocrine symptoms include polycythemia,masculinity or male breast development.The prognosis of ACC is poor,and the classification and staging of the tumor and hypercortisol are associated with the prognosis.Surgical resection is the first choice,but the recurrence rate of the tumor is high and the overall survival rate is low after operation.In this paper,the clinical characteristics,diagnosis,differential diagnosis,prognosis and treatment of ACC are summarized by reviewing the past researches.

Objective: To investigate the clinical features of chromophobe renal cell carcinoma (chRCC) and analyze the factors affecting its prognosis. Methods: Retrospectively analyze the case data of 66 patients with chRCC admitted to Beijing Friendship Hospital, Capital Medical University from October 2003 to September 2018, including 32 males and 34 females; the average age was (53.9±13.9) years and the age range was 24-85 years. To analyze the clinical symptoms, whether have hypertension, diabetes, tumor characteristics (size, side, location), surgical methods, TNM staging and other clinical features of patients, with disease-free survival (DFS) as the study endpoint. The survival curve was drawed by the kaplan-Meier method. Survival analysis was performed using Log-rank test, and the clinical features of prognosis were analyzed by Cox regression models. Results: Among the 66 patients, the mean diameter of the tumor was (5.4±3.5) cm, 17 cases were ≥7 cm, 49 cases were <7 cm; 48 cases were asymptomatic, and 18 cases were symptomatic; 45 cases in T₁, 15 cases in T₂, 6 cases in T₃; 33 cases were underwent radical nephrectomy, 32 cases were underwent nephron sparing surgery, 1 case was under the therapy of watchful waiting. The median follow-up time was 61 months, and the DFS in 1, 5, and 10 years were 94.6%, 91.3%, and 82.2%, respectively. Log-rank results showed that the maximum diameter of the tumor was related to the T stage and the survival time of the patients (P<0.05). Cox multivariate analysis showed that T stage was an independent risk factor for DFS (HR=8.102, P=0.027). Conclusions ChRCC is a type of kidney cancer with a good prognosis. Tumor staging is more common in T₁ and T₂ phases, patients with higher DFS in 5 and 10 years, and T staging is an independent risk factor for DFS in patients.

Small cell carcinoma of the kidney is an uncommon tumor with high degree of malignity,rapid progress,and most of the metastatic lesions at diagnosis.There is no specific difference between small cell carcinoma of the kidney and other renal parenchymal tumors in the clinical features and imaging findings.Diagnosis is mainly based on pathology.There is no unified guidance in the treatment,and the main ways include surgery alone,chemotherapy alone,and adjuvant chemotherapy after surgery.Targeted drugs are expected to become a new therapeutic modality for renal small cell carcinoma.In this paper,the clinical features,diagnosis and differential diagnosis,treatment and prognosis of renal smcc will be summarized through the analysis of domestic and external research progress.

Metabolic disease is a cluster of metabolic abnormalities,including hypertension,diabetes,obesity,dyslipidemia,hyperuricemia,etc.The incidence rate of metabolic disease has increased in recent years.Metabolic diseases are closely related to the occurrence,development and prognosis of renal carcinoma.This article aims to summarize research progress on the correlation between metabolic diseases and renal carcinoma so that we could provide valuable information for the prevention,treatment and prognosis of renal carcinoma.